India Globalization Capital Inc (IGC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, India Globalization Capital Inc (IGC) has a cash flow conversion efficiency ratio of -0.258x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.09 Million) by net assets ($8.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IGC equity financing ratio to measure how much of total assets are equity-financed.
India Globalization Capital Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how India Globalization Capital Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check India Globalization Capital Inc (IGC) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
India Globalization Capital Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of India Globalization Capital Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yeong Hwa Meta
KO:012280
|
0.097x |
|
Food and Drinks Public Company Limited
BK:F&D
|
0.004x |
|
Besra Gold Inc
AU:BEZ
|
0.034x |
|
Chumpower Machinery Corp
TWO:4575
|
0.030x |
|
FN REPUBLIC Co. Ltd
KQ:064090
|
0.025x |
|
Morgan Sindall Group PLC
LSE:MGNS
|
0.296x |
|
Genoray Co. Ltd
KQ:122310
|
0.057x |
|
Nord Insuretech Group AB
ST:NORDIG
|
0.533x |
Annual Cash Flow Conversion Efficiency for India Globalization Capital Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of India Globalization Capital Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see India Globalization Capital Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.33 Million | $-4.79 Million | -0.758x | -6.67% |
| 2024-03-31 | $7.32 Million | $-5.20 Million | -0.710x | -50.26% |
| 2023-03-31 | $14.91 Million | $-7.05 Million | -0.473x | -51.32% |
| 2022-03-31 | $23.89 Million | $-7.46 Million | -0.312x | +5.14% |
| 2021-03-31 | $32.80 Million | $-10.80 Million | -0.329x | -0.69% |
| 2020-03-31 | $26.54 Million | $-8.68 Million | -0.327x | -229.65% |
| 2019-03-31 | $33.57 Million | $-3.33 Million | -0.099x | +58.58% |
| 2018-03-31 | $8.06 Million | $-1.93 Million | -0.239x | -26.52% |
| 2017-03-31 | $7.35 Million | $-1.39 Million | -0.189x | -1573.88% |
| 2016-03-31 | $13.95 Million | $-157.70K | -0.011x | +93.55% |
| 2015-03-31 | $14.75 Million | $-2.58 Million | -0.175x | -42.23% |
| 2014-03-31 | $14.15 Million | $-1.74 Million | -0.123x | -1134.88% |
| 2013-03-31 | $14.97 Million | $178.20K | 0.012x | +103.75% |
| 2012-03-31 | $15.82 Million | $-5.02 Million | -0.318x | +12.10% |
| 2011-03-31 | $7.29 Million | $-2.63 Million | -0.361x | -219.70% |
| 2010-03-31 | $26.15 Million | $-2.96 Million | -0.113x | +47.27% |
| 2009-03-31 | $37.86 Million | $-8.11 Million | -0.214x | -2.22% |
| 2008-03-31 | $40.87 Million | $-8.57 Million | -0.210x | -611.92% |
| 2007-03-31 | $52.92 Million | $-1.56 Million | -0.029x | -1451.85% |
| 2006-03-31 | $50.17 Million | $-95.21K | -0.002x | -- |
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more